CARGO Therapeutics Reports 71 Patients Dosed In Phase 2 Firicabtagene Autoleucel Study; Interim Results Expected H1'25; FDA Clears IND For CRG-023, Phase 1 Enrollment Mid-2025; Announces Novel Allogeneic Platform For CAR T-Cell Therapy
Express News | CARGO Therapeutics: Believe Cash, Cash Equivalents Will Be Sufficient to Fund Our Expected Operations Through 2026
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options
Clear Street Launches Healthcare & Biotechnology Equity Research
